Physician profile
Ryan Bretz
NPI 1982262192
$2,391.04
in general payments reported to CMS, 2019-2025
13 companies · $634 in 2025
The $634 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.00 · 2022: $332 · 2023: $574 · 2024: $835 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $772.81 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $589.99 | 2022-2025 | Xiidra, Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $444.47 | 2023-2025 | Acuvue |
| Alcon Vision LLC | $285.90 | 2022-2025 | Total30, Precision 1, Precision7 |
| Oyster Point Pharma, INC. | $76.92 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $40.58 | 2023-2025 | Cequa |
| Allergan, INC. | $36.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.04 | 2022-2023 | |
| Dompe US, INC. | $28.48 | 2024 | Oxervate |
| Abbvie INC. | $28.07 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $20.79 | 2024 | Xdemvy |
| Thea Pharma INC. | $19.93 | 2023 | |
| Kala Pharmaceuticals, INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bretz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.